<DOC>
	<DOCNO>NCT00003726</DOCNO>
	<brief_summary>RATIONALE : Anticoagulants , lepirudin , may help prevent blood clot form patient receive chemotherapy small cell lung cancer . PURPOSE : This phase I/II trial study side effect best dose lepirudin treat patient recurrent advance small cell lung cancer .</brief_summary>
	<brief_title>Lepirudin Treating Patients With Recurrent Advanced Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dose , safety , antitumor response rate lepirudin patient recurrent extensive stage small cell lung cancer previously treat chemotherapy . OUTLINE : This dose escalation ( individual patient ) study . Patients receive dose escalate lepirudin subcutaneously twice day 3-4 day . Dose escalation continue patient aPTT prolongation occur maximum dose level reach . The patient continue treatment maximum tolerate dose . Treatment continue absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 20-35 patient accrue study within 18-24 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lepirudin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : 1 . Pathologically confirm recurrent extensive stage small cell lung cancer . 2 . Received least one prior chemotherapy regimen 3 . Measurable evaluable disease irradiate 4 . No pleural effusion , bone metastasis , brain metastasis , elevate serum enzyme , radionuclide scan sole indicator lesion 5 . Brain metastasis allow patient receive cranial irradiation clinical evidence brain metastasis PATIENT CHARACTERISTICS : 1 . Age : Not specify 2 . Performance status : Karnofsky 60100 % 3 . Life expectancy : Not specify 4 . Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 5 . Hepatic : Bilirubin great 2.0 mg/dL PT aPTT normal 6 . Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min 7 . Cardiovascular : No unstable heart rhythm No unstable angina No clinical evidence congestive heart failure No prior cerebrovascular accident stroke No uncontrolled severe hypertension 8 . Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 9 . At least 6 week since sign symptom bleed No history bleed disorder 10 . No bacterial endocarditis active infection PRIOR CONCURRENT THERAPY : 1 . Biologic therapy : Not specify 2 . Chemotherapy : At least 3 week since prior chemotherapy 3 . Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy 4 . Surgery : At least 6 week since major surgery , trauma , needle biopsy organ 5 . Other : No concurrent anticoagulant platelet inhibitor therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
</DOC>